Annovis Bio, Inc. · NYSE:ANVS
Annovis Bio — IPO Roadshow (December 2019)
24 slides from Annovis Bio's IPO roadshow presentation, Dec 10, 2019
Slide 1: Disclaimer
DISCLAIMER We have filed a registration statement (including a preliminary prospectus) with the Securities and Exchange Commission, or the SEC, for the offering to which this presentation relates. This document does not provide full disclosure of all material facts relating to the securities offered
Slide 2: Offering Summary
OFFERING SUMMARY ANNOVIS BIO, Inc. ISSUER: Proposed Aggregate Offering $ 10.0 Million $6.00 -$8.00 Price Range ANVS – NYSE American Proposed Symbol 1.4 million Shares Offered Pre-IPO Common Shares as Converted 4.5 million Post-IPO Common Shares Outstanding 5.9 million To advance the clinical develop
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS A novel approach to treat neurodegeneration is desperately needed Annovis is developing drugs for Alzheimer's (AD) and Parkinson's disease (PD), including the orphan indication Alzheimer's in Down Syndrome (AD-DS) Three patented families of compounds Lead compound, ANVS401, is
Slide 4: The State of Alzheimer's Disease
THE STATE OF ALZHEIMER’S DISEASE Alzheimer's is the most common cause of dementia, general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for 60 to 80 percent of dementia cases. a 1 in 6 females and 1 in 11 males have the
Slide 5: Alzheimer's Drug Trial Failures
ALZHEIMER’S DRUG TRIAL FAILURES Have researchers been on the wrong track with amyloid? The idea that sticky brain plaques cause Alzheimer’s disease began as an interesting hypothesis and eventually became drug industry dogma. Now, after a string of clinical trial failures, that hypothesis looks less
Slide 6: Annovis' New 3-Prong Approach to Attack AD and PD
ANNOVIS’ NEW, 3-PRONG APPROACH TO ATTACK AD AND PD Chronic and acute brain insults lead to high levels of neurotoxic proteins and to neurodegeneration aSynuclein Parkinson’s - Alzheimer’s aSYN Targeting Compounds Tau Amyloid β Alzheimer’s - Parkinson’s Aβ Targeting Compounds Tauopathies - Alzheimer’
Slide 7: Pipeline
PIPELINE Oral drug for chronic indications injectable drug for acute traumatic events oral drug for advanced and dementia 8 NEUROTOXIC PROTEIN DISEASETARGET PRE-CLINICAL IND PHASE 1 PHASE 2 ADAPP, tau, aSYN AD-DSAPP, tau, aSYN PDaSYN, APP, tau TBItau, APP, aSYN AdvancedBChEl ADAD
Slide 8: Corporate Multi-layer Strategy Patent Estate
CORPORATE Multi-layer strategy PATENT ESTATE Method of Use: Acute Brain and Nerve Injuries Composition Methods of Use: Method of Use: Process for Production of Matter and Method of Use pK/pD, Dose, Formulations Prevention and Treatment Patent/Application Subject Matter Status US Expiry US ANVS401 an
Slide 9: How Nerve Cells Work
HOW NERVE CELLS WORK In healthy nerve cells little packages containing neurotransmitters or nerve growth factors travel unimpaired from the cell body through the axon to the synapse. NEUROTRANSITTERS THAT TRAVEL ACCROSS THE AXON Adrenaline Noradrenaline Dopamine SYNAPSE SOMA & CELL BODY DENDRITES Se
Slide 10: Neurotoxic Proteins Impair Axonal Transport and Cause a Toxic Cascade
NEUROTOXIC PROTEINS IMPAIR AXONAL TRANSPORT AND CAUSE A TOXIC CASCADE ANVS401 IMPROVES AXONAL TRANSPORT AND IMPEDES THE TOXIC CASCADE HIGH LEVELS OF NEUROTOXIC PROTEINS IMPAIRED AXONAL TRANSPORT SLOWER SYNAPTIC TRANSMISSION INFLAMMATION DEATH OF NERVE CELLS LOSS OF COGNITIVE AND MOTOR FUNCTION ANVS4
Slide 11: Neurodegeneration Disease Is an Axonal Transport Disease
NEURODEGENERATION DISEASE IS AN AXONAL TRANSPORT Retrograde (0.5 frame/sec) Normal Transport The Normal Flow and Speed of vesicles carrying BDNF across the axon. Axonal transport is responsible for: Neurotransmitters GABA (anxiety), ACh (cognition), dopamine (movement), serotonin (mood) Abnormal Tra
Slide 12: What Does Impaired Axonal Transport Mean for Your Health?
WHAT DOES IMPAIRED AXONAL TRANSPORT MEAN FOR YOUR HEALTH? Everything we do is regulated by our brain. The brain sends its directives via axon to the targets, be they in the brain or in the body Therefore everything we do is regulated by neurotransmitters Acetylcholine stimulates cognition and low le
Slide 13: Results in Humans
RESULTS IN HUMANS ANVS401 Lowers Neurotoxic Proteins in Spinal Fluid of MCI Patients Maccecchini et al: JNNP 2012; 83: 894-902 In this proof of concept study, ANVS401 lowers the levels of APP/Aβ, tau/p-tau and αSYN back to the levels seen in healthy volunteers It lowers the levels of the three neuro
Slide 14: ANVS401 Lowers Neurotoxic Proteins and Inflammatory Markers
ANVS401 LOWERS NEUROTOXIC PROTEINS AND INFLAMMATORY MARKERS CSF Biomarkers Significantly Decrease After 10 Days of Oral ANVS401 in MCI Patients CSF Inflammatory Markers Significantly Decrease After 10 Days of Oral ANVS401 in MCI Patients Human Biomarker CSF % of Baseline Inflammatory Protein CSF % o
Slide 15: Two Phase 2a Clinical Trials in AD and PD
TWO PHASE 2 CLINICAL TRIALS IN AD AND PD TWO PHASE 3 CLINICAL TRIALS IN AD-DS AND PD 16 P A T I E N T SE N D P O I N T S AD-DS with 100 patients forCognitive Outcomes 24 months PD with 400 patients forFunctional Outcomes 18 months P A T I E N T SE N D P O I N T S AD with 24 patients for one month (o
Slide 16: Results in Animals
RESULTS IN ANIMALS 19 animal studies showed that ANVS401 and ANVS405 improved the affected function 17 ANVS401 and ANVS405 increased memory and learning in three animal models: AD tg mice DS trisomic mice TBI rats Improved gut motility in PD tg mice Stabilized brain chemistry in FTD tau tg mice Prot
Slide 17: Market Projections
MARKET PROJECTIONS Increase in Incidence with Aging of Population 47% 4% 2% 1% 60-65 65-70 70-75 75-80 80-85 85+ Source: Alzheimer‘s Association 2014; Incidence of AD in Relation to Age Annual sales potential for US and worldwide are over $100 billion dollars 18 16% 8%
Slide 18: Planned Use of Proceeds
PLANNED USE OF PROCEEDS IPO Proceeds $ 1 0 ,0 0 0 ,0 0 0 * In August 2019, Annovis r eceived an NIH grant for $ 1.7 million that fully covers the costs associated with the chronic toxicology studies 19 Use of Proceeds Through 2021 Phase 2a Trial in PD$3,000,000 Phase 2a Trial in AD800,000 Chronic To
Slide 19: ANVS401 Development Plans
ANVS401 DEVELOPMENT PLANS IPO SECONDARY OFFERING 20 POST-IPO DEVELOPMENT PLAN 2019 2020 2021 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Long term animal tox Additional GMP material Phase 2 AD Silk study Phase 2 AD - PD study Phase 2 PD dose titration FDA Meeting Begin Phase 3 in AD-DS and PD
Slide 20: Chief Executives and Chief Advisors
CHIEF EXECUTIVES AND CHIEF ADVISORS Maria L. Maccecchini, PhD Founder, President & CEO Founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel
Slide 21: Board of Directors
BOARD OF DIRECTORS Michael B. Hoffman Chairman Mr. Hoffman is the Founder and Managing Partner of Stone Capital Partners, a private equity firm focused on power and renewable energy. He was Partner of Riverstone, senior managing director at the Blackstone Group and managing director at Smith Barney,
Slide 22: Investment Summary
INVESTMENT SUMMARY A novel approach to treat neurodegeneration is desperately needed The markets for AD and PD drugs are in the multibillions of dollars and growing Annovis has a novel solution to stop the course of AD and PD ANVS401 improves axonal transport and homeostasis in the brain and recover
Slide 23: Contact Us
CONTACT US 1055 Westlakes Drive Suite 300 Berwyn, PA 19312 Improves T H E F L O Wof Axonal Transport in Alzheimer’s Disease and Neurodegeneration +1 (610) 727 3913 info@annovisbio.com www.annovisbio.com Proposed Symbol: ANVS (NYSE American)
Slide 24: Annovis Bio
NOVIS | of Axonal Transport eimer’s Disease and Neurodegeneration Improves THE > ANVS401 ANVS405 ANVS301 >. Proposed Symbol: ANVS (NYSE American) ___ a \ Wits. es 1055,Westlakes Drive ‘ * Suite 300 Berwyn, PA 19312 es +1 (610) 7293913 info@annovisbio:;com www.annovisbio.com